Looking for the Biotech Breakout

One sector that has been standing out in my scans is the Biotech sector. While the Biotech Ishares (IBB) still has some work to do with the chart before it breaks out to new highs, there are a number of stocks breaking out and other stocks in this sector building solid bases that could move higher if the overall market turns bullish. Below the chart are some stock ideas in this industry.

Anadys Pharmaceuticals (ANDS), Cypress Bioscience (CYPB), CV Therapeutics (CVTX), Valeant Pharmaceuticals (VRX), Illumina (ILMN), Biogen Idec (BIIB), Life Technologies (LIFE), Sequenom (SQNM), BioMarin Pharmaceutical (BMRN)

Here is an article from SeekingAlpha that talks about all things biotech: Searching for the Best Biotech ETF.

Comments

[diramCHK:]

Many biotech companies are indeed in the hedge of important technological breakthroughs but they have still a long way to go until they can show a marginal profit on the stock values.
One of these companies is the israeli-based D-Medical biomed firm (Nilimedics, G-Sense, SinDolor Medical) engaged among other products in a III-level program for a new insuline pump-type for diabetic users.
The company has already made important progress in the R&D and expect important developments. Worth to watch.

Jan 19 08:27 AM

[jimmy Turano:]

RE:BIOTECH COMPANIES AND INVESTORS
When do you think the SEC will begin enforcing its rules and regulations to weed out many who do not comply. Besides many of these companies are Cash Poor and have been existing for decades, while their investors are getting slaughtered left and right. And the Research firms, their experts, their high target prices, who follow these Biotech companies are misleading investors with their high target stock prices and 5 star ratings for years. Some investors are waiting 25 years already for FDA APPROVALS/Big Revenues and ultimate success overall. But the only ones making money is management, even if they have No Products. All they do is give promising News Releases to feed the Investors appetites.

Jan 19 08:40 AM

[richwolol:]

How can you report the pending breakout of Biotechs, including BIIB but not ELN. The drug Tysabri is co-owned (50%) owned by each company

Jan 19 09:05 AM

[Furd Turgeson:]

BIIB also has Avonex and Rituxan to go along with Tysabri. Both Avonex and Rituxan are multi-billion dollar blockbusters. Beyond that, the major difference is BIIB has over 4 billion in revenue and is a profitable cash cow.

Jan 19 09:47 AM

[Jake2:]

Cramer says IBB is no good. Buy CELG, he says. Cramer knows all.

Jan 19 06:01 PM